These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30968857)

  • 1. [Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.].
    Santeufemia DA; Miolo G
    Recenti Prog Med; 2019 Mar; 110(3):3e-5e. PubMed ID: 30968857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not all pains are the same: breakthrough pain in cancer patients. A case report].
    Gunnellini M
    Recenti Prog Med; 2018 Nov; 109(11):6e-10e. PubMed ID: 30565580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2017 Sep; 17(3):419-425. PubMed ID: 28744772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
    Romualdi P; Candeletti S
    Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain.
    Davies A; Mundin G; Vriens J; Webber K; Buchanan A; Waghorn M
    J Pain Symptom Manage; 2016 Mar; 51(3):538-45. PubMed ID: 26706627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
    Núñez-Olarte JM; Alvarez-Jiménez P
    J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
    Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
    PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transmucosal fentanyl and breakthrough pain: The other side of the coin].
    Henche Ruiz AI
    Rev Esp Geriatr Gerontol; 2020; 55(1):56-57. PubMed ID: 31307779
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
    Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
    Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
    England R; Maddocks M; Manderson C; Zadora-Chrzastowska S; Wilcock A
    BMJ Support Palliat Care; 2011 Dec; 1(3):349-51. PubMed ID: 24653483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
    Coombes L; Burke K; Anderson AK
    Scand J Pain; 2017 Oct; 17():256-259. PubMed ID: 29229211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of oral formulations of fentanyl for breakthrough cancer pain.
    Handsaker S; Dempsey L; Fabby C
    Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.